- CIIX
CEO said company will employ social media as it markets new CBD products
starting March 2020
- CIIX
subsidiary CBD Biotech Co. focused on driving growth, building online
sales to younger demographics in China
- Goals
of CIIX strategy include profitability, expansion of market, maximized
impact
ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren
Wang said the company will adopt social media multiplatform techniques to
market new CBD products beginning in March 2020. The move is designed to boost
online sales to a younger demographic in China through its subsidiary CBD
Biotech, explained Wang during a MoneyTV interview with host
Donald Baillargeon. In the interview, Wang also outlined the company’s path to
profitability in fiscal 2020 and 2021.
“CBD Biotech’s goal in 2020 is to make a profit,” Wang
stated in the interview. “That is the key of the stock market. That’s the key
for our stock price. That’s the key for our shareholders. CIIX plans to launch
a breakthrough CBD product in March. It will debut through its B2B partners
through social media, such as TikTok, and target in China a lot of young
people.”
One important aspect of the company’s strategy to increase
profit is to sell its new CBD product through e-commerce using different social
media platforms in 2020. Wang observed that multi-platform social media would
play a key role in the company’s marketing to a younger consumer audience of
its CBD line. He specifically mentioned using platforms such as TikTok in the
campaign, which launched in 2017 and accrued 500 million users in its first two
years. Recently hailed as a “must for every small business,” social media
marketing gives companies more direct access to their customers, meeting them
where they are in a cost-effective way. Social media marketing has also been
linked with increased brand recognition (http://ibn.fm/YOANZ), allowing companies to “target and
retarget ideal consumers.” CIIX hopes to engage audiences of all ages through
social media as it increases traction for its new CBD offerings.
In addition to its anticipated CBD product, CBD Biotech
currently markets a line of hemp-infused cosmetics products in China. Wang
estimates that cosmetics could deliver profit margins of 10-20 times for the
company (http://ibn.fm/G89BP).
“That’s quite a big profit,” he noted.
Referencing the high gross margins of CBD cosmetics, Wang
said the company is working to bring more of that profitability down to the
bottom line through lower costs and a restructuring. Wang explained that CIIX
intends to expand its market as it maximizes sales through a split
configuration of its B2B and B2C divisions.
The B2C division would focus on marketing and selling to
consumers while the B2B division would be responsible for maximizing revenue to
wholesalers and through multilevel social media outlets, he explained. The
combined aim of the two divisions is to raise sales, cut costs and achieve
profitability, he said.
Wang sees subsidiary CBD Biotech company reaching
profitability by Q4 2020 fiscal year and continuing into 2021. “I am very
positive about CBD in 2020, very excited,” he concluded.
CIIX is a diverse company driven not only by sales of
cosmetics, hemp wine and CBD but also educational services. CIIX offers its
audience of Chinese-speaking investors real-time market commentary, analysis
and educational-related services in Chinese character language sets.
For more information, visit the company’s website at www.ChineseInvestors.com
NOTE TO INVESTORS: The latest news and updates
relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
